Citations

Showing 10 of 108162 citations.

Impact of Interim Hospitalizations on Risk of Venous Thromboembolism (VTE) Recurrence: A Nested Case-Cohort Study
Ashrani, Aneel A. , Farmer, Sara A., Petterson, Tanya M. , Bailey, Kent R. , Leibson, Cynthia L., Heit, John A.

Mayo Clinic

Blood | October 13, 2019 | Volume: 118 | Issue: 21 | Pages: 1241-1241

10.1182/blood.v118.21.1241.1241 Get It

Abstract Abstract 1241 Background: Hospitalization (with or without surgery) is a major risk factor for incident venous thromboembolism (VTE); however, the contribution of interim hospitalization to risk of recurrent VTE is unknown. Objective: To estimate risk of recurrent VTE related to interim hospitalization by conducting a population-based longitudinal review of provider-linked detailed medical records. Methods: We performed a nested case-cohort study. The cohort consisted of all Olmsted County residents with incident VTE 1988–2000 and ≥1 day follow-up. Cases were cohort members with recurrent VTE. Subjects were followed for all interim hospitalizations and warfarin use from incident VTE until earliest of emigration, death, recurrent VTE, or 12/31/2005. Data were analyzed using Cox proportional hazards and time dependent covariates to test for the effects of interim hospitalization and prophylaxis on VTE recurrence, adjusting for gender and age at incident VTE. Analyses were limited to subjects who survived free of death and recurrent VTE for ≥ 6 months. Results: Of 1262 incident VTE events (cohort), there were 309 VTE recurrences (cases). We randomly sampled 272 subjects from the cohort and 163 cases. Of the random samples, 210 incident events and 83 cases survived ≥ 6 months free of death and recurrent VTE and form our analysis population. The rate of secondary (interim) prophylaxis was approximately 50% for both incident events and cases, and was not predictive of recurrence (p=0.73). Male gender and interim hospitalization were associated with increased VTE recurrence even after adjusting for age at incident VTE and use of secondary warfarin prophylaxis. The hazard of recurrent VTE was nearly 10-fold higher for subjects with interim hospitalization versus those with none (HR: 9.6; 95% CI: 6.6, 13.8); men had a 1.5-fold increased recurrence rate compared with women (HR: 1.5; 95% CI: 1.1, 2.1). Conclusions: Our results, for the first time, show the importance of interim hospitalization as a predictor of VTE recurrence. Disclosures: No relevant conflicts of interest to declare.
Plasma Cell Folate Receptor Overexpression Differentiates Multiple Myeloma from Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma.
Cascino, G. D., Kimlinger, Teresa K. , Prendergast, Franklyn G., Greipp, Philip R., Greipp, Patricia T. , Rajkumar, S. Vincent , Fonseca, Rafaël , Bergsagel, P. Leif , Low, Philip S.

Mayo Clinic

Blood | October 13, 2019 | Volume: 104 | Issue: 11 | Pages: 3649-3649

10.1182/blood.v104.11.3649.3649 Get It

Abstract Background: Folate receptor (FR) is a recently recognized tumor marker that is being investigated for targeted delivery of drugs, imaging of cancer cells, and tumor immunotherapy. The small size of the molecule, simple conjugation chemistry and lack of immunogenicity make folate an ideal candidate for targeted delivery to tumors bearing the FR (Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002 Sep 13;54(5):675–93). FR is overexpressed in 90% of ovarian cancers and in other human tumors including endometrial, colorectal, breast, and neuroendocrine carcinomas, it is negatively or only weakly expressed in most normal tissues including some myeloid cells. In view of the above we wished to learn if overexpression of FR by marrow plasma cells (PC) might differentiate MM from MGUS and SMM. Methods: We obtained marrow biopsy sections from 20 patients each with MM, MGUS, or SMM, and 11 normals and stained them by immunohistochemistry using a FR-beta antibody. Expression was graded 0 (negative), 1 (equivocal), 2 (positive) or 3 (strong positive) based on immunohistochemical staining of marrow PC. We recorded the percent PC, percent positive PC, and the staining of other cell types including myeloid, erythroid, lymphocytes, macrophages, megakaryocytes and control tissues. Results: PC of patients with MM positively expressed FR compared to MGUS, SMM and normal PC (p<0.0001) (Figure 1 and 2). Of interest, 6 of 20 SMM patients showed positive expression. Maturing myeloid cells were also positive, acting as internal positive controls. Macrophages were often positive; some endothelial cells were positive; early erythroid precursors were rarely positive; megakaryocytes, maturing erythroid precursors and lymphocytes did not express FR. The chromosomal location of the FOLR gene cluster is 11q13. Gene expression arrays of purified PC failed to show evidence of overexpression of FOLR1, FOLR2, or FOLR3. We are currently performing Western blots to examine levels of protein product of purified PC. Conclusion: Immunohistochemistal studies show differential expression of FR in MM PC compared to absent or equivocal expression in MGUS and normal PC and variable expression in SMM. The data suggest that FR may be used as a diagnostic tumor marker and has implications for development of folate-based tumor imaging, drug delivery, and immunotherapy. Figure Figure Figure Figure
Allogeneic Stem Cell Transplantation (SCT) in Untreated First Relapse or Following Re-Induction Chemotherapy for Patients with Acute Myeloid Leukemia (AML).
Pornvipavee, Rachanid, Kremers, Walter K. , Pedersen, Rachel, Elliott, Michelle A. , Tefferi, Ayalew , Litzow, Mark R. , Kremers, Walter K , Hogan, William J.

Mayo Clinic

Blood | October 13, 2019 | Volume: 104 | Issue: 11 | Pages: 5143-5143

10.1182/blood.v104.11.5143.5143 Get It

Abstract Background The timing of SCT for treatment of AML after first relapse is controversial, i.e.,whether to proceed to SCT at the time of relapse or to proceed to chemotherapy re-induction first in an attempt to reach a second remission. The purpose of this study is to determine the optimal time of allogeneic SCT in AML patients in first relapse by comparing outcomes of allogeneic SCT between patients untreated and patients post re-induction chemotherapy. Method This retrospective study was approved by the Mayo Foundation IRB. Between February 1983 and March 2003, 60 patients with AML in untreated first relapse (REL1) or post re-induction chemotherapy (CT) underwent allogeneic SCT in Mayo Clinic, Rochester. Study outcome included overall survival (OS), disease free survival (DFS), and transplant related mortality (TRM). The outcome was compared between the patients who underwent allogeneic SCT at REL1 and CT. Survival was analyzed using Kaplan-Meier (KM) and groups were compared statistically with the log-rank test. Result Of the 60 patients receiving allogeneic SCT , 25 patients and 35 patients underwent SCT at REL1 and CT, respectively. In the group of CT, 23 patients (66%) achieved CR2 while 12 patients (34%) had refractory disease. Forty-nine of 60 patients received cyclophosphamide and total body irradiation (Cy/TBI) as a conditioning regimen and the remainder received busulfan and cyclophosphamide( Bu/Cy). Patients in REL1 were older at SCT (median age 38 vs 31 years p= 0.024 ) and had lower percentage blast cells in bone marrow at first relapse (median 15% vs 50% p=0.00095) than in CT group. Difference in other baseline characteristics were not significant. KM analysis showed that the two groups did not show statistically differences in OS (p=0.43), DFS (p=0.68), and TRM (p=0.25). However, there were trends toward longer median OS (26.2 vs 5.4 months) and DFS (11.9 vs 3.3 months) with REL1 versus CT. OS at 1 year was 56 % for REL1 and 34.3 % for CT and at 5 year 32.1 % and 28.6 %, respectively. DFS at 1 year was 48 % for REL1 and 31.4 % for CT and at 5 years 22.9 % and 24.5 % respectively. TRM at 1 year was 25% for REL1 and 40 % for CT. A univariate Cox Proportional Hazard analysis for survival showed that unfavorable cytogenetics at diagnosis and relapse, antecedent MDS, and shorter duration of CR1 were significantly associated with a higher risk of death. Higher percentage of blast cells in bone marrow at first relapse was not significantly associated with a higher risk of death. In a multivariate model, unfavorable cytogenetics at first relapse and shorter duration of CR1 were both significantly associated with an increased risk of death. In this study, even after adjusting for other factors in a multivariate model, the difference between REL1 and CT groups was not statistically significant. Conclusion This study suggests that outcome of allogeneic SCT was comparable between REL1 and CT. Patients with AML in first relapse may proceed to allogeneic SCT because there appear to be no statistical differences in REL1 versus re-induction chemotherapy before SCT. REL1 patients tended to have a better outcome than CT patients.
Carbon Monoxide Therapy Modulates Hematopoietic Stem Cell Development in Heme-Oxygenase-1 Knockout Mice
Beckman, Joan D. , Marker, Paul H., Nguyen, Julia , Croatt, Anthony J., Nath, Karl A. , Hebbel, Robert P. , Vercellotti, Gregory M. , Belcher, John D. , Beckman, Joan D

Mayo Clinic

Blood | October 13, 2019 | Volume: 118 | Issue: 21 | Pages: 1318-1318

10.1182/blood.v118.21.1318.1318 Get It

Abstract Abstract 1318 Previous studies have demonstrated that heme-oxygenase-1 (HO-1), the rate limiting enzyme in the catabolism of heme, is a regulator of the balance between hematopoiesis and stem cell preservation under stress. HO-1−/− mice display oxidative stress, anemia, and leukocytosis with chronic inflammation. We hypothesize that therapy with inhaled carbon monoxide (CO), a by-product of HO-1 activity with antioxidant and anti-apoptotic properties; will reduce stress hematopoiesis in HO-1−/− mice, reducing inflammation and redistributing hematopoietic potential. In order to test this hypothesis we treated 25 week old HO-1−/− mice and HO-1+/+ mice (n=7/strain) with 250 ppm inhaled CO for 1 h/day, 3 days/week for eight weeks and compared them to an equal number of untreated HO-1−/− and HO-1+/+ mice. After 8-weeks of treatment the mice were sacrificed and flow cytometry was performed on bone marrow to assess hematopoietic potential. Cell cycle analysis of the bone marrow demonstrates that untreated HO-1−/− mice have a significantly decreased percent of cells in S-phase compared to untreated HO-1+/+ mice. Treatment with CO significantly (p<0.05) increases the percent of cells in S-phase in HO-1−/− mice but not HO-1+/+ mice. Reactive oxygen species (ROS) production in lineage−, c-kit+, Sca-1+ (KLS) cell population was assessed using 5-(and 6-)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate dye. HO-1−/− mice have a significantly (p<0.001) increased proportion of ROS positive KLS cells compared with HO-1+/+ mice. Analysis of long-term (LT), short-term, and multipotent (MPP) progenitor cell populations was conducted. Treatment with CO significantly (p<0.05) increases the percent of LT-HSC and MPP progenitor cells in HO-1−/− mice but not HO-1+/+ mice. Concordantly, the total white blood cell count of the CO-treated mice increased significantly. The differential of the mature blood cells demonstrates significant shift in cell maturation, with significant increase in red blood cells, platelets, and lymphocytes and a significant decrease in monocytes. Combined this data indicates that CO therapy is able to modify the hematopoietic potential of HO-1−/− mice leading to a change in mature cell populations. We propose a model in which CO-mediated signaling initiates a homeostatic conditioning program in stem cells to balance hematopoiesis and stem cell preservation, ultimately leading to a change in the inflammatory milieu of the mice. Disclosures: Belcher: Sangart, Inc: Research Funding. Vercellotti:Sangart, Inc: Research Funding.
Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome
Kapoor, Prashant , Kumar, Shaji , Lacy, Martha Q. , Hayman, Suzanne R. , Dalton, Robert J., Reeder, Craig B. , Lust, John A., Zeldenrust, Steven R., Stewart, Keith, Kyle, Robert A. , Greipp, Philip R., Fonseca, Rafaël , Witzig, Thomas E. , Dispenzieri, Angela , Buadi, Francis K. , Bergsagel, P. Leif , Gertz, Morie A. , Mıkhael, Joseph , Dingli, David , Roy, Vivek , Rajkumar, S. Vincent

Mayo Clinic

Blood | October 13, 2019 | Volume: 112 | Issue: 11 | Pages: 95-95

10.1182/blood.v112.11.95.95 Get It

Abstract Background: Multiple myeloma (MM) is a heterogeneous disease with very divergent outcomes that are dictated in a large part by specific cytogenetic abnormalities, as well as other prognostic factors such as the proliferative rate of marrow plasma cells. Prognostic systems incorporating these factors have shown clinical utility in identifying high-risk patients, and are increasingly being utilized for treatment decision-making. However, the prognostic relevance of these factors may change with the application of novel therapies. The objective of this study was to determine the impact of risk-stratification (incorporating plasma cell metaphase cytogenetics, interphase fluorescent in-situ hybridization (FISH) and the slide-based plasma cell labeling index (PCLI)) in a cohort of patients with newly diagnosed MM treated initially with lenalidomide + dexamethasone (Rev-Dex). Methods: From March 2004 to November 2007, 100 consecutive patients treated with Rev (25mg/day) on days 1 through 21 of a 4-week cycle in combination with dexamethasone as initial therapy for newly diagnosed myeloma, were identified. High-risk MM was defined as presence of any one or more of the following: hypodiploidy, monoallelic loss of chromosome 13 or its long arm (by metaphase cytogenetics only), deletion of p53 (locus 17p13) or PCLI ≥ 3% or immunoglobulin heavy chain (IgH) translocations, t(4;14) (p16.3;q32) or t(14;16)(q32;q23) on FISH. PFS and OS survival estimates were created using the Kaplan Meier method, and compared by log-rank tests. Results: The median estimated follow-up of the entire cohort (N=100) was 36 months. The median PFS was 31 months; the median OS has not been reached. The 2- and 3-year OS estimates were 93% and 83%, respectively. 16% patients were deemed high-risk by at least one of the 3 tests (cytogenetics, FISH or PCLI). Response rates (PR or better) were 81% versus 89% in the high-risk and standard risk groups, respectively, P=NS; corresponding values for CR plus VGPR rates were 38% and 45% respectively. The median PFS was 18.5 months in high-risk patients compared to 37 months in the standard-risk patients (n=84), P<0.001(Figure). Corresponding values for TTP were 18.5 months and 36.5 months, respectively, P=<0.001. OS was not statistically significant between the two groups; 92% 2-year OS was noted in both the groups. Overall, 95 patients had at least one of the 3 tests to determine risk, while 55 patients could be adequately stratified based on the availability of all the 3 tests, or at least one test result that led to their inclusion in the high-risk category. The significant difference in PFS persisted even when the analysis was restricted to the 55 patients classified using this stringent criterion; 18.5 months vs. 36.5 months in the high-risk and standard- risk groups respectively; P<0.001. In a separate analysis, patients who underwent SCT before the disease progression were censored on the date of SCT to negate its effect, and PFS was still inferior in the high-risk group (p=0.002). Conclusion: The TTP and PFS of high-risk MM patients are inferior to that of the standard-risk patients treated with Rev-Dex, indicating that the current genetic and proliferation-based risk-stratification model remains prognostic with novel therapy. However, the TTP, PFS, and OS obtained in high-risk patients treated with Rev-Dex in this study is comparable to overall results in all myeloma patients reported in recent phase III trials. In addition, no significant impact of high-risk features on OS is apparent so far. Longer follow-up is needed to determine the impact of risk stratification on the OS of patients treated with Rev-Dex. Figure Figure
Driving T Cell Development in the Thymus.
Ogle, Brenda M. , João, Cristina , Cascalho, Marília , Platt, Jeffrey L.

Mayo Clinic

Blood | October 13, 2019 | Volume: 104 | Issue: 11 | Pages: 3860-3860

10.1182/blood.v104.11.3860.3860 Get It

Abstract Background: Classic reports on lymphocyte development hold that B and T cells develop independently. This concept derives in part from the observation that patients with pure B cell immunodeficiency and hypogammaglobulinemia have a normal thymus and T cell numbers. Our recent findings however challenge this concept. We found that T cell development depends not only on the interaction of T cell precursors with thymic epithelial cells but also on other cells. Here we report that those other cells are B cells. Aims: The purpose of this study was to determine whether B cells drive T cell development and TCR diversification in the thymus. Methods: We compared the number of sub-populations of thymocytes and TCR repertoire diversity in B-cell deficient and B-cell proficient mice and in B cell deficient mice following immunoglobulin (Ig) injections. Total leucocytes numbers were determined with a Coulter counter and numbers of thymocytes sub-populations were calculated by flow cytometry analysis. TCR repertoire diversity was measured by a novel method based on hybridization of TCR Vβ specific cRNA on a gene chip platform. Results: In B-cell deficient mice the number of thymocytes was four times reduced and TCR Vβ chain diversity was up to one million times lower compared with wild type mice. Numbers and diversity were restored by treatment of the mice with gamma globulin (see table). Conclusions: T cell development and diversification is driven by B cells. Mice Number of total thymocytes (mean ± standard deviation) p Value β V TCR diversity of thymocytes (median; min.-max.) p Value C57BL/6 (wild mice) 1.3 x 108 ± 5.1 x 107N=7 4.7 x 106; 1.0 x 105 − 1.1 x 108N=5 JH−/− (B cell immunodeficient mice) 3.1 x 107 ± 1.7 x107N=7 0.002 5.9 x 102; 3.6 x 102 − 1.1 x 103N=5 0.0002 JH−/− treated with Ig 3.9 x 107 ± 1.4 x106N=2 0.20 1.1 x 105; 2.7 x 100 − 7.7 x 105N=4 0.08
A Phase II Trial of Gleevec™ in Patients with Refractory/Relapsed Myeloma.
Lacy, Martha Q. , Geyer, Susan M. , Kimlinger, Teresa K. , Greipp, Philip R., Lust, John A., Zeldenrust, Steven R., Hayman, Susazanne R., Dispenzieri, Angela , Witzig, Thomas E. , Rajkumar, S. Vincent , Fonseca, Rafaël , Gertz, Morie A.

Mayo Clinic

Blood | October 13, 2019 | Volume: 104 | Issue: 11 | Pages: 2420-2420

10.1182/blood.v104.11.2420.2420 Get It

Abstract Background: Though STI-571 (Gleevec™) was designed to specifically inhibit the bcr-abl gene product, it inhibits other receptor tyrosine kinases at physiologically attainable concentrations, including c-kit (steel factor receptor, stem cell factor receptor, SCF-R or CD 117). Studies have shown that about one-third of patients with multiple myeloma or monoclonal gammopathy of undetermined significance have plasma cells that display reactivity for c-kit. Others have shown that several myeloma cell lines and fresh myeloma bone marrow cells proliferate in response to stem cell factor. mRNA transcripts for c-kit ligand and, more commonly, its receptor have been detected in myeloma cell lines RPMI 8226, JJN3, U266 B1, NCI-H929, ARH77 and HS-Sultan by RT-PCR. Methods: Patients were eligible for study if they presented with relapsed or refractory myeloma, an ECOG performance score < 3, ability to sign informed consent, serum creatinine <3.5 mg/dL, direct bilirubin <2 mg/dL, alkaline phosphatase <750 U/L, absolute neutrophil count > .5 x 10(9)/L and platelet count > 50 x 10(9)/L. Patients were treated with Gleevec™ 400 mg po qd. The purpose of the study was to assess the response rate of the drug Gleevec™ in patients with relapsed multiple myeloma. Secondary objectives included assessment of the tolerability of the regimen in this cohort of patients and to correlation between disease response and c-kit positivity (CD117) by flow cytometry. Results: Overall, 23 patients were enrolled between 12/01 and 11/02, of which 16 were male and 12 had a prior PBSCT. Median age was 63 years (range: 49 – 82), and the baseline performance scores were 0 (8 patients), 1 (10), and 2 (4). Median time from MM diagnosis to enrollment was 57 months (range: 11 – 133). Patients were high risk with a median PCLI of 1.3 (range: 0 – 23%) and a median beta-2 microglobulin of 4.6 (range: 1.4 – 10.1). Eleven of 21 tested patients had positive CD117 (≥20%) staining of their bone marrow plasma cells by flow cytometry. None were PDGF positive. The treatment was well tolerated. After treatment with Gleevec™, there were only 3 non-hematologic grade 3 or 4 toxicities, and they occurred in 1 patient: he developed a capillary leak type syndrome, ascites, and dyspnea as part of his terminal phase of myeloma which included evolution into plasma cell leukemia. Grade 3 myelosuppression was observed in a minority of patients: thrombocytopenia (3), neutropenia (1), and anemia (3). There were no responses, and no patients are currently receiving treatment. Patients ended treatment due to progressive disease (18 patients), death on study (3), adverse reactions (1), and other reasons (1). The median duration of treatment was 48 days (range: 12 to 349). Of the 7 patients who remained on study for more than 60 days, CD117 status was as follows: positive (4); negative (3); not ascertained (1). As of August 2004, 12 patients have died. Conclusions: Though forty-eight percent of the enrolled myeloma patients were CD117 positive, providing a putative target for the Gleevec™, no responses were seen in this high risk population of relapsed patients. Further study will be necessary to determine the significance of the observed stabilization of disease in 36% of the CD117 positive patients.
Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.
Hideshima, Teru , Chauhan, Dharminder , Ishitsuka, Kenji , Mitsiades, Constantine S. , Kumar, Shaji , Hideshima, Hiromasa, Munshi, Nikhil C. , Richardson, Paul G. , Schenkein, David P., Tassone, Pierfrancesco , Raje, Noopur , Hamasaki, Makoto, Richardson, Paul Gerard Guy , Anderson, Kenneth C.

Mayo Clinic

Blood | October 13, 2019 | Volume: 104 | Issue: 11 | Pages: 2351-2351

10.1182/blood.v104.11.2351.2351 Get It

Abstract NF-κB is a transcriptional factor promoting tumor cell growth and inhibition of apoptosis via regulating expression of proteins modulating cell cycle and anti-apoptosis. NF-κB is constitutively associated with an inhibitor (IκB), which is phosphorylated by IκB kinase (IKK) upon cell stimulation (ie, TNFα) and subsequently degraded by ubiquitin-proteasome pathway, thereby allowing NF-κB to translocate to nucleus. We have previously shown that an IKK inhibitor PS-1145 partially (20–50%) inhibits MM cell proliferation; however, it inhibits both IL-6 secretion from BMSCs triggered by MM cell adhesion and proliferation of MM cells adherent to BMSCs. Targeting IKKβ is therefore a possible therapeutic option for inhibition of MM cell growth in the bone marrow microenvironment by downregulating NF-κB activity. In this study, we further delineated the biologic significance of IKK inhibition in MM cells using IKKβ specific inhibitor MLN120B (Millennium Pharmaceuticals, Cambridge, MA). MLN120B induced 60–90% growth inhibition in cells from the MM cell lines RPMI8226, RPMI/Dox40, RPMI/LR5, U266, and INA-6; on the other hand, it induced only 25–30% inhibition in MM.1S and MM.1R cells, assessed by 72 h tritiated-thymidine uptake. Importantly, neither IL-6 nor IGF-1 overcomes the growth inhibitory effect of MLN120B in both MM.1S and U266 cells. Interestingly, MLN120B significantly augmented TNFα-induced cytotoxicity in MM.1S cells. We next examined whether MLN120B could enhance the cytotoxicity of other agents. MLN120B augmented growth inhibition triggered by doxorubicin and melphalan in RPMI8226 and IL-6 dependent INA-6 cell line. We therefore studied growth inhibitory effect of MLN120B in the presence of bone marrow stromal cells (BMSCs). MLN120B inhibited 70–80% of constitutive IL-6 secretion from BMSCs, without toxicity. Importantly, MLN120B almost completely blocked stimulation of MM.1S, U266 and INA-4 cell growth and IL-6 secretion from BMSCs induced by binding of tumor cells to BMSCs. Finally, MLN120B overcame the protective effect of BMSCs, cell adhesion mediated drug resistance, against dexamethasone in MM.1S cells. Taken together, our data demonstrate that an IKKβ inhibitor induces cytotoxicity in MM cells in the BM milieu, providing the framework for clinical trials of these novel agents to improve patient outcome in MM.
A Novel Splicing Mutation in the Gene Encoding the Chromatin-Associated Factor ATRX Associated with Acquired Hemoglobin H Disease in Myelodysplastic Syndrome (ATMDS).
Fisher, Chris, Steensma, David P. , Allen, Steven L. , Gibbons, Richard J. , Fisher, Christopher A., Higgs, Douglas R.

Mayo Clinic

Blood | October 13, 2019 | Volume: 104 | Issue: 11 | Pages: 3606-3606

10.1182/blood.v104.11.3606.3606 Get It

Abstract Acquired hemoglobin H (HbH) disease (α thalassemia) can arise in the setting of marrow neoplasia, especially the myelodysplastic syndrome (MDS). This association has been termed α thalassemia-MDS (ATMDS, MIM #300448). Recently, we have linked ATMDS to acquired point mutations in the ATRX gene, which encodes an X-linked chromatin-associated factor whose precise normal cellular function is unknown (Steensma et al, Blood2004;103:2019, and Gibbons et al, Nature Genetics2003;34:446). We now describe a novel acquired splicing mutation in the helicase domain of the ATRX gene in a 71 year-old man of southern Italian descent. The patient, who previously had normal blood indices, presented with a 6-month history of microcytic anemia (Hb 7.7 g/dL, MCV 73.7 fL, reticulocytes 0.2%; WBC 11,800/uL with 29% circulating blasts). Peripheral smear demonstrated marked anisopoikilocytosis and the presence of poorly hemoglobinized ghost cells, while a marrow aspirate and biopsy revealed dysplastic features including atypical megakaryocytes, and approximately 20% blasts, consistent with a diagnosis of MDS in leukemic transformation. On supravital staining, approximately 30% of circulating erythrocytes contained HbH inclusions. The α/β globin transcript ratio measured by quantitative real-time PCR ranged between 0.11 and 0.39, compared with the mean ratio for 11 normals (α/β ratios in normals ranged between 0.8–1.2 fold of the mean). Despite this evidence of α thalassemia, no gross rearrangements of the α globin cluster were detected on Southern blotting or by FISH, and sequencing of the α globin genes was unremarkable. Screening of the entire coding region of the ATRX gene by denaturing high-performance liquid chromatograpy showed no abnormalities. Amplification and sequencing of cDNA made from the patient’s blood, however, revealed loss of ATRX exon 28 (in the middle of the putative helicase domain), resulting in a frame shift and generation of a premature stop codon. The causative mutation at the genomic level remains unknown, despite sequencing of the consensus splice sites framing both ATRX exon 28 and the surrounding regions. A clonally restricted mutation in a distant cryptic splice enhancer or inhibitor is suspected. Following treatment with idarubicin and Ara-C, the patient achieved a complete remission with normalization of red cell morphology and indices, and HbH was no longer detectable. This case emphasizes the need to search carefully for abnormal mRNA splicing when screening for ATRX mutations and provides further support for a link between ATRX mutations and ATMDS. Among 20 ATMDS patients analyzed molecularly, we have now characterized ATRX missense, null, and nonsense mutations in 9 patients, found a codon substitution of uncertain significance in 1 patient, and detected ATRX splicing mutations in 3 patients, including the present case. Additionally, one patient had an acquired α globin deletion limited to the neoplastic clone (Steensma et al, Blood2004; 103:1518). The molecular defect remains unknown in 6 cases. Since RNA is not available from these 6 archival cases, it is possible that they have ATRX splicing mutations as well.
Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia
Butterfield, JH, Leiferman, KM, Abrams, J S, Silver, JE, Bower, James H., Gonchoroff, Nick J., Gleich, GJ

Mayo Clinic

Blood | October 13, 2019 | Volume: 79 | Issue: 3 | Pages: 688-692

10.1182/blood.v79.3.688.688 Get It

Abstract The syndrome of episodic angioedema and eosinophilia is characterized by cyclic edema, marked peripheral blood eosinophilia, and eosinophil degranulation in the dermis. Using a sensitive immunoenzymetric method, we measured serum interleukin (IL)-5 levels in four patients with this syndrome. We also determined the percentage of activated T cells in the peripheral blood of a new patient before and during an attack. In the patient presented, IL-5 levels peaked several days before maximal eosinophilia and then declined. This patient's lymphocytes showed an increased percentage, 28% (normal 2% to 3%), of activated T cells staining for both CD3 and HLA-DR 10 days before maximal eosinophilia, but no increase at the time of peak eosinophilia. In serum from three previously reported cases, elevated serum IL-5 levels were found during attacks. After glucocorticoid administration, IL-5 levels became undetectable in three of the four patients. Production of IL-5 is likely an important determinant of the pathophysiology of this syndrome.